Last reviewed · How we verify
Enteris BioPharma Inc. — Portfolio Competitive Intelligence Brief
1 marketed
0 filed
0 Phase 3
3 Phase 2
0 Phase 1
Live · 30-min refresh
Portfolio leaders (marketed + Phase 3 / filed)
| Drug | Generic | Phase | Class | Target | Area | First approval |
|---|---|---|---|---|---|---|
| Leuprolide Depot | Leuprolide Depot | marketed | GnRH agonist | GnRH receptor | Oncology; Urology; Gynecology |
Therapeutic area mix
- Oncology; Urology; Gynecology · 1
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Competitive overlap (companies sharing drug classes)
- AbbVie (prior sponsor, Abbott) · 1 shared drug class
- Abbott · 1 shared drug class
- Bayer · 1 shared drug class
- Changchun GeneScience Pharmaceutical Co., Ltd. · 1 shared drug class
- Chesapeake Urology Research Associates · 1 shared drug class
- Chong Qing Reproducive and Genetic Institute · 1 shared drug class
- Colorado Center for Reproductive Medicine · 1 shared drug class
- AbbVie · 1 shared drug class
Subscribe to ongoing alerts
Every new pipeline event for Enteris BioPharma Inc.:
- Enteris BioPharma Inc. pipeline updates — RSS
- Enteris BioPharma Inc. pipeline updates — Atom
- Enteris BioPharma Inc. pipeline updates — JSON
Cite this brief
Drug Landscape (2026). Enteris BioPharma Inc. — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/enteris-biopharma-inc. Accessed 2026-05-16.